PacBio (PACB) Q1 2026 earnings review
Record Consumables Clouded by Instrument Weakness and Margin Compression
PacBio's Q1 2026 results show a business leaning heavily on its recurring revenue base while struggling to place new hardware. Total revenue was stable flat at $37.2M YoY, but the composition shifted: consumable revenue accelerated to a record $21.8M, but instrument revenue dropped 12% to $9.7M. The new Vega system, previously a growth driver, disappointed with placements decelerating to just 27 units. Consequently, management deployed promotions that, combined with rising compute component costs and warranty charges, caused non-GAAP gross margins to reverse from 40% a year ago down to 37%. While GAAP net loss optically improved to $8.3M, this was heavily skewed by a one-time $45.8M gain from divesting short-read assets. FY26 guidance targets $165-$175M in revenue, indicating modest expectations for hardware recovery.
🐂 Bull Case
Consumable revenue grew 8.5% YoY to $21.8M, representing nearly 59% of total revenue. The installed base is highly engaged, particularly in clinical settings.
Non-GAAP OpEx dropped to $49.9M (from $61.7M a year ago). The $48.1M net cash injection from the short-read asset sale significantly extends the cash runway.
🐻 Bear Case
Vega placements dropped to 27 (down from 42 last quarter and 28 a year ago). If PacBio cannot sell instruments, future consumable growth will eventually hit a ceiling.
Despite a favorable mix-shift toward high-margin consumables, non-GAAP gross margin contracted 300 bps YoY due to promotions, warranty issues, and component inflation.
⚖️ Verdict: ⚪
Neutral. The core technology adoption is solid, proven by record consumables and the SPRQ-Nx rollout. However, weak instrument sales and contracting margins suggest pricing power and capital equipment demand remain problematic.
Key Themes
Margin Reversal Contradicts Favorable Mix
Reversing the narrative of margin expansion seen in 2025, Q1 2026 non-GAAP gross margin compressed to 37% from 40% a year ago. A higher ratio of consumable sales typically expands margins, yet PacBio experienced the opposite. Management explicitly cited increased computing component costs, temporary Vega promotions, and warranty charges. This contradicts the positive narrative and reveals vulnerability in hardware profitability and quality control.
Vega Placements Decelerating Sharply
The Vega system, intended to drive "land and expand" strategies for smaller labs, is decelerating. PacBio placed just 27 units in Q1 2026, down from 42 in 25Q4 and slightly below the 28 units placed during its launch quarter (25Q1). CEO Christian Henry admitted instrument revenue was "lower than we had expected," which explains why margin-dilutive promotions were necessary to move units.
Macro Inflation Hitting Hardware COGS
Global macroeconomic pressures, specifically rising costs for computer memory and processing components, were cited as a primary headwind to gross margins. This macro reality exposes PacBio's hardware-heavy cost structure to ongoing semiconductor and supply chain inflation.
Consumables Provide a Stable Floor
Consumable revenue remains the strongest pillar of the business, accelerating 8.5% YoY to a record $21.8M. EMEA revenue grew 17% YoY, directly attributed to increased clinical utilization. This steady recurring revenue provides a vital cushion against volatile capital equipment cycles.
SPRQ-Nx Commercial Rollout
After a successful beta program that yielded "positive early feedback on the new chemistry," PacBio is initiating a broad commercial rollout of the SPRQ-Nx chemistry to all Revio customers. This technological innovation drastically lowers the cost of whole genome sequencing, which management believes will "catalyze consumable growth and Revio instrument demand."
Asset Sale Injects Vital Cash
PacBio officially closed the sale of its short-read sequencing assets to Illumina, yielding $48.1M in net cash proceeds and generating a $45.8M gain. This finalizes their strategic pivot purely to long-read sequencing, fortifies the balance sheet ($276.0M ending cash), and effectively funds another full year of operations at the current cash burn rate.
Other KPIs
Decelerating slightly from ~$236,000 in Q1 2025 and ~$242,000 in Q4 2025. While still within historical targets, the slight downward trend suggests that new placements might be going to lower-throughput customers, or that higher-yield chemistries are reducing the sheer volume of kits needed per genome.
The company recorded a one-time GAAP operating expense for a settlement and related legal fees with Personal Genomics of Taiwan. This cash outflow partially offsets the liquidity benefits gained from the short-read asset sale.
Guidance
Accelerating. The midpoint of $170M implies roughly 6.25% YoY growth over FY25's $160.0M. While an acceleration from FY25's sluggish 4% growth, it remains a modest target that relies heavily on a successful SPRQ-Nx rollout to stimulate back-half instrument demand.
Key Questions
Vega Demand Funnel
Vega placements fell short of expectations and required margin-dilutive promotions to move. Is this weakness a function of macro capital constraints, or are you facing tougher competition in the benchtop sequencer market?
Duration of Component Cost Inflation
How long do you expect the elevated computing component costs to suppress gross margins, and have you considered pricing adjustments on instruments to offset them?
Impact of SPRQ-Nx on Pull-Through
With the broad commercial rollout of SPRQ-Nx, how do you model the elasticity of demand? Will the lower cost-per-genome drive enough volume to offset the lower price per sample, or should we expect a temporary dip in Revio pull-through metrics?
Cash Runway Update
Accounting for the $48.1M short-read asset sale proceeds and the $16.3M litigation settlement, has your internal timeline for achieving cash flow positivity changed from your prior 'exiting 2027' target?